The rise in spending was driven largely by inventory buildup in anticipation of the commercial launch of Viaskin Peanut, pending U.S. approval, as well as clinical expenses related to the COMFORT Toddlers study and headcount expansion.

Furthermore, SG&A expenses rose by 4.6 million USD year-on-year, reflecting increased staffing levels and market research efforts ahead of the potential U.S. commercialization of Viaskin Peanut.

The biotech firm's operating income totaled 5.6 million USD in 2025, up from 4.2 million USD the previous year, mainly due to an increase in activities eligible for research tax credits.

DBV reported cash and cash equivalents of 194 million USD as of December 31, 2025. Supplemented by 94 million USD in additional gross proceeds received on January 16, 2026, the company expects its current runway to fund operations through the second quarter of 2027.